Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tc 99m Tilmanocept Imaging in Colorectal Carcinoma Liver Metastases
NCT03029988Phase 1Terminated
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- Jul 2017
- Primary completion
- Sep 2018
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 1
01
Overview
Phase 1, open-label trial of technetium tc 99m tilmanocept in colorectal carcinoma (CRC) (2 cohorts), sponsored by Navidea Biopharmaceuticals, Inc. Primary endpoint: Visualization of Lesions by FDG PET/CT Imaging and by Tc 99m Tilmanocept SPECT/CT Imaging. Started Jul 2017; status: terminated.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT03029988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03029988.